510:. Kazia reported positive study results for the newly diagnosed, unmethylated population in the concurrent analysis which compares patients treated with paxalisib between January 2021 and March 2022 with those treated with temozolomide during the same time. The results showed a clinically meaningful increase in medium overall survival of 3.8 months, representing an increase of 33% vs. the temozolomide arm which is currently the standard of care.
17:
1632:
184:; codenamed INK1197, IPI-145; PIK3CD and PIK3CG inhibitor): FDA-approved on 24 September 2018 for treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies, and treatment of relapsed or refractory follicular lymphoma after at least two prior systemic therapies.
220:(MZL) after at least one prior anti-CD20-based regimen, and treatment of relapsed or refractory follicular lymphoma after at least three prior lines of systemic therapy. As of May 31, 2022, umbralisib was withdrawn from the US market due to the decrement in overall survival and increased serious adverse events when using umbralisib.
594:(codenamed PF-05212384, PKI-587; PIK3CA, PIK3CG and mTOR inhibitor) has undergone several phase II trials as a potential treatment for different cancers, most of which have been terminated for different reasons. As of March 2022, two phase II trials on breast cancer are still recruiting patients.
71:
regulates cellular functions such as growth and survival. It is strictly regulated in healthy cells, but is always active in many cancer cells, allowing the cancer cells to better survive and multiply. PI3K inhibitors block the PI3K/AKT/mTOR pathway and thus slow down cancer growth. They are examples
610:(codenamed GSK2269557; PIK3CD inhibitor) has undergone several phase II trials as a potential treatment for different respiratory diseases (asthma and COPD) as well as for APDS/PASLI, all of which have been completed or terminated as of March 2022. Results are available for all of these trials.
3292:
Locatelli SL, Stirparo GG, Tartari S, Saba E, Rubino L, Brusamolino E, Castagna L, Santoro A, Carlo-Stella C (2013). "The PI3K/ERK Dual
Inhibitor AEZS-136 Induces ROS-Dependent Necroptotic Cell Death and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts".
443:
that lead to approval of idelalisib by FDA and EMA for treatment of patients with CLL. All other phase III trials testing idelalisib-based therapy as an experimental treatment, e.g. in first-line CLL and second-line NHL, had been terminated by end of 2016, mainly due to increased toxicity and
1847:
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, et al. (January 2018). "Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind,
349:
with placebo + rituximab in patients with relapsed iNHL. Study completion is expected for
January 2023. Preliminary results show a strong and significant improvement of progression-free survival under copanlisib treatment, but also considerably more severe and serious side
1996:
Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, et al. (May 2021). "Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial".
2553:
for "A Study
Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer" at
337:
was planned as a placebo-controlled randomized phase III trial with about 190 patients. However, recruitment was stopped after 25 patients were included and the trial continues as a non-randomized single-arm trial. Results are expected for
November
558:(codenamed GDC-0980, GNE 390, RG7422; pan-class I PI3K and mTOR inhibitor) has undergone four phase II trials as a potential treatment for different solid tumours, three of which have been completed or terminated as of March 2022.
2516:
for "A Study of
Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)" at
385:(RTB-101-205) was terminated by the sponsor. Dactolisib has also undergone several phase II trials as a potential treatment for solid tumours as well as for respiratory diseases, most of which have been terminated as of 2022.
1833:
for "Phase III Study of BKM120/Placebo With
Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)" at
1781:"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial"
736:(codenamed GSK2126458, GSK458) has completed two phase I trials in 2015 and 2016, respectively. No data have been published for these trials and no further trials have been conducted since then as of March 2022.
511:
2245:
for "A Study of
Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)" at
3491:
622:(codenamed SAR245408 and XL147; inhibitor of PIK3CA, PIK3CD, and PIK3CG) has undergone several phase II trials as a potential treatment for different solid tumours, all of which have been completed as of 2022.
543:). The trial is currently recruiting patients as of March 2022 and will compare inavolisib + palbociclib + fulvestrant with placebo + palbociclib + fulvestrant. Results are expected for September 2025.
672:(codenamed RP6530; dual PIK3CD and PIK3CG inhibitor) is undergoing several phase II trials as a potential treatment for different cancers. Two single-arm trials (in CLL and iNHL) have reported results.
2358:
for "Study of LOXO-305 Versus
Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)" at
760:(CH5132799, PA799; mainly a PIK3CA inhibitor) will be tested in a phase I/II trial with PIK3CA-mutated colorectal cancer patients that is currently recruiting patients as of March 2022.
648:(codenamed MLN1117 and TAK-117; PIK3CA inhibitor) is undergoing several phase II trials as a potential treatment for different cancers. As of March 2022, results have been reported for
742:(PIK3CA and PIK3CD inhibitor) has completed one phase I trial in 2016. No data have been published for this trial and no further trials have been conducted since then as of March 2022.
730:(codenamed CAL-120, GS-9820) has completed one phase I trial in 2016. No data have been published for this trial and no further trials have been conducted since then as of March 2022.
700:(PIK3CB inhibitor) has undergone several phase II trials as a potential treatment for different cancers, one of which have been completed, with no results published as of March 2022.
568:
dual PI3K/mTOR inhibitor) has undergone several phase II trials as a potential treatment for different solid tumours, all of which have been completed or terminated as of March 2022.
533:. The trial is currently recruiting patients as of March 2022 and will compare zandelisib + rituximab to chemotherapy (CHOP regimen) + rituximab. Results are expected for April 2026.
616:(codenamed GDC-0941; pan-class I PI3K inhibitor) has undergone five phase II trials as a potential treatment for different solid tumours, with no results published as of March 2022.
574:(codenamed IPI-549; PIK3CD inhibitor) is currently undergoing three phase II trials as a potential treatment for different solid tumours, with no published results as of March 2022.
1947:
for "A Study of the
Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (BELLE-4)" at
632:
inhibitor) has undergone several phase II trials as a potential treatment for different cancers, three of which have been completed or terminated and have results as of March 2022.
1442:
Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, et al. (February 2010). "Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors".
1888:
for "A Phase III Study of BKM120 With
Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi (BELLE-3)" at
114:(PIK3CD). All PI3K inhibitors that are currently approved inhibit one or more p110 isoforms of the class I PI3Ks. Inhibiting different p110 isoforms can have different effects, e.g.
2497:
1609:
996:
Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA (October 2021). "Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020)".
3369:
Heffron TP, Berry M, Castanedo G, Chang C, Chuckowree I, Dotson J, et al. (April 2010). "Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor".
2394:
for "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)" at
1559:"FDA Approval for duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"
1903:"A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)"
326:(codenamed BAY 80-6946; predominantly a PIK3CA and PIK3CD inhibitor) ist currently undergoing three phase III trials, all of which are testing it in patients with indolent
76:. While PI3K inhibitors are an effective treatment, they can have very severe side effects and are therefore only used if other treatments have failed or are not suitable.
428:
comparing duvelisib + rituximab with rituximab alone in patients with follicular lymphoma was terminated by the sponsor when it was no longer expected to lead to approval.
198:; codenamed BYL719; PIK3CA inhibitor): FDA-approved in May 2019 for treatment of HR-positive and HER2/neu-negative breast cancer in combination with the endocrine therapy
3518:
2985:
694:(PIK3CB and PIK3CD inhibitor) will be tested as a potential treatment for gastric cancer in a phase II trial that is currently recruiting patients as of March 2022.
2875:
for "A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer" at
244:). The trial was completed in August 2021 and results have become available in March 2022. Another phase II/III trial for APDS/PASLI that serves as an extension study (
2412:
for "A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (CITADEL-310)" at
3077:
Garlich JR, Becker MD, Shelton CF, Qi W, Liu X, Cooke L, Mahadevan D (2010). "Phase I Study of Novel Prodrug Dual PI3K/MTOR Inhibitor SF1126 in B-Cell Malignancies".
2972:
for "Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)" at
2727:"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors"
2430:
for "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)" at
1426:
666:
derivative) has undergone several phase II trials as a potential treatment for different solid tumours, all of which have been completed or terminated as of 2022.
361:
regimen) with placebo + immunochemotherapy in patients with relapsed iNHL who have received 1–3 previous lines of therapy. Results are expected for February 2023.
152:-approved in July 2014 for treatment of three types of blood cancers: treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with
754:(dual pan-class I PI3K and mTOR inhibitor): The phase I trial of this drug was terminated due to lack of sufficient exposure following single- and repeat-dosing.
519:(codenamed GDC-0032, RG7604; PIK3CA inhibitor): Development was discontinued due to strong side effects and only a minor survival benefit in the phase III trial
5243:
79:
After PI3K inhibitors had been under investigation as anti-cancer drugs for several years, the first one to be approved for treatment in clinical practice was
4218:
1310:
249:
2060:"NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas"
1039:
Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong (2021).
2857:
for "MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma" at
3406:"Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941"
488:
502:(codenamed GDC-0084; pan-class I PI3K and mTOR inhibitor) was tested as a potential treatment for newly diagnosed, unmethylated as well as recurrent
1384:
Ito K, Caramori G, Adcock IM (April 2007). "Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease".
306:
comparing buparlisib + fulvestrant with fulvestrant alone in patients with breast cancer both showed excessive side effects. The phase II/III trial
444:
mortality. Two trials comparing new experimental treatments to idelalisib as a comparator and a dose optimization study in FL are still ongoing.
792:
450:(codenamed INCB050465, INCB 50465; PIK3CD inhibitor) will be tested as a potential treatment for different diseases in five phase III trials:
5194:
3511:
2890:"The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures"
688:(PIK3CD inhibitor) has undergone a phase II trial as a potential treatment for HNSCC. The trial was terminated in 2018 due to safety reasons.
2264:
for "Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)" at
2045:
for "Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)" at
1181:
588:(DLBCL) was completed in 2019 but its results have not yet been published. Other phase II trials with fimepinostat have been terminated.
539:(codenamed GDC-0077; PIK3CA inhibitor) will be tested as a potential treatment for PIK3CA-mutant breast cancer in a phase II/III trial (
2297:
5238:
3953:
3909:
3787:
1572:
3712:
3183:
for "Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber" at
714:, one of the most widely studied dual PI3K/mTOR inhibitors. A phase II trial with SF1126 has been terminated due to slow enrolment.
678:(codenamed SAR245409, XL765; pan-class I PI3K inhibitor and weaker inhibitor of mTOR), in trial for B-cell lymphomas, e.g. CLL and
2632:
for "Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations" at
2340:
for "A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL" at
1237:
Maira SM, Stauffer F, Schnell C, García-Echeverría C (February 2009). "PI3K inhibitors for cancer treatment: where do we stand?".
3504:
2498:"Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer"
2466:
for "Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)" at
1088:
Curigliano G, Shah RR (February 2019). "Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology".
122:
2227:
for "A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07" at
170:; codenamed BAY 80-6946; predominantly a PIK3CA and PIK3CD inhibitor): FDA-approved in September 2017 for treatment of relapsed
4434:
4228:
381:
in generally healthy elderly people. However, the trial did not meet this endpoint. Consequently, the related phase III trial
59:) are a class of medical drugs that are mainly used to treat advanced cancers. They function by inhibiting one or more of the
4847:
3849:
3739:
402:
led to its approval for CLL/SLL An extension trial to DUO was completed in 2020, but its results have not yet been published.
2448:
for "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)" at
3165:
for "Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours" at
2954:
for "Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)" at
4769:
4752:
4627:
4391:
3769:
585:
233:
4501:
4097:
1615:
1577:
149:
5211:
4703:
3496:
3456:
Williams R, Berndt A, Miller S, Hon WC, Zhang X (August 2009). "Form and flexibility in phosphoinositide 3-kinases".
3883:
2112:
for "A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly" at
565:
5248:
5069:
4949:
4939:
311:
156:, treatment of relapsed small lymphocytic lymphoma after at least two prior systemic therapies, and treatment of
91:
60:
3109:
for "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes" at
604:
in several phase II trials that are currently recruiting or scheduled to recruit patients as of March 2022.
5121:
5054:
5024:
4642:
3892:
1272:
Heavey S, O'Byrne KJ, Gately K (April 2014). "Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC".
370:
267:
2535:
for "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)" at
2209:
for "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)" at
1592:
529:(codenamed ME-401; PIK3CD inhibitor) will be tested as a potential treatment for iNHL in the phase III trial
5199:
5106:
4924:
4639:
4125:
3973:
3900:
548:
292:
3201:
for "Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma" at
1558:
1544:
5004:
4994:
4727:
4569:
457:
217:
2484:
for "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)" at
4276:
4093:
4063:
3923:
2308:
1983:
for "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)" at
867:
64:
21:
16:
310:
comparing buparlisib + paclitaxel with paclitaxel alone in patients with breast cancer did not improve
600:(codenamed YY-20394; PIK3CD inhibitor) will be tested as a potential treatment for different types of
4674:
4551:
4072:
3988:
3057:
2705:
2184:
1185:
649:
638:(codenamed UCB-5857; PIK3CD inhibitor) has undergone one phase II trial as a potential treatment for
466:
418:
327:
289:
95:
3252:
2814:
2794:
4959:
4859:
4838:
4559:
4381:
4213:
3944:
3840:
3232:
3140:
2774:
2685:
2645:
2567:
679:
639:
453:
378:
171:
157:
3272:
2665:
2607:
2277:
1610:"FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma"
577:
41:
4017:
3220:
3202:
3184:
3166:
3128:
3110:
3045:
3027:
3009:
2973:
2955:
2929:
2876:
2858:
2840:
2633:
2587:
2555:
2536:
2518:
2485:
2467:
2449:
2431:
2413:
2395:
2377:
2359:
2341:
2265:
2247:
2228:
2210:
2172:
2171:
for "Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly" at
2148:
2113:
2046:
2022:
1984:
1966:
1948:
1889:
1835:
1767:
1749:
1682:
1482:
Crabbe T (April 2007). "Exploring the potential of PI3K inhibitors for inflammation and cancer".
1409:
1363:
1113:
1021:
814:
653:
645:
635:
625:
619:
607:
597:
561:
5166:
1199:
Wu P, Liu T, Hu Y (2009). "PI3K inhibitors for cancer therapy: what has been achieved so far?".
751:
733:
697:
555:
4047:
4027:
4012:
769:
669:
499:
5141:
4715:
3549:
3473:
3435:
3386:
3351:
2911:
2756:
2089:
2014:
1924:
1865:
1810:
1766:
for "The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN)" at
1725:
1528:
1499:
1459:
1401:
1355:
1289:
1254:
1216:
1162:
1105:
1070:
1013:
975:
926:
788:
763:
727:
707:
142:
1901:
Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, et al. (February 2017).
824:
804:
775:
757:
739:
691:
5146:
4903:
4618:
4252:
4237:
3958:
3465:
3425:
3417:
3378:
3341:
3333:
3302:
3086:
3008:
for "A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia" at
2901:
2746:
2738:
2138:
2079:
2071:
2006:
1914:
1857:
1800:
1792:
1715:
1707:
1694:
Rao VK, Webster S, Dalm VA, Šedivá A, van Hagen PM, Holland S, et al. (November 2017).
1521:
1491:
1451:
1393:
1345:
1337:
1281:
1246:
1208:
1152:
1144:
1097:
1060:
1052:
1005:
965:
957:
916:
906:
840:
745:
703:
73:
1696:"Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib"
1041:"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives"
369:(codenamed BEZ235, NVP-BEZ235; dual pan-class I PI3K and mTOR inhibitor) was tested in the
4585:
4547:
4338:
3760:
3675:
2321:
798:
83:
in 2014. Several others followed, and even more are still under development (see below).
2127:"RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial"
1779:
Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, et al. (July 2017).
436:
has undergone eleven phase III clinical trials as of March 2022. These include the
5205:
4739:
4330:
3824:
3688:
3575:
3545:
3532:
3430:
3405:
3346:
3321:
2751:
2726:
2725:
Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. (January 2015).
2084:
2059:
1805:
1780:
1720:
1695:
1350:
1325:
1157:
1132:
1065:
1040:
970:
945:
921:
894:
581:
68:
20:
Overview of phosphoinositide 3-kinase (PI3K) inhibitors and their interaction with the
3404:
Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, et al. (July 2009).
2010:
1861:
1796:
5232:
5079:
5039:
4409:
4282:
4163:
4106:
3864:
3813:
3322:"B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells"
2152:
2026:
1636:
1367:
1025:
946:"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism"
475:
437:
237:
3306:
3127:
for "A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies" at
3090:
2888:
Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT (September 2007).
1117:
314:
and was stopped for futility at the end of phase II. These results led the sponsor,
5126:
5090:
4974:
4964:
4918:
4914:
4876:
4784:
4574:
4513:
4509:
4490:
4485:
4464:
4453:
4267:
4261:
4247:
4242:
4173:
4168:
4121:
4007:
3874:
3854:
3783:
3732:
3722:
3536:
3528:
2058:
Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, et al. (August 2009).
1413:
503:
414:
3421:
3215:
3197:
3179:
3161:
3123:
3105:
3040:
3022:
3004:
2968:
2950:
2906:
2889:
2871:
2853:
2835:
2742:
2628:
2549:
2531:
2512:
2480:
2462:
2444:
2426:
2408:
2390:
2372:
2354:
2336:
2260:
2241:
2223:
2205:
2167:
2108:
2075:
2041:
1979:
1961:
1943:
1884:
1829:
1762:
1748:
for "Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI" at
1744:
1677:
1455:
1427:
Study results provide rationale for use of PI3K inhibitors in therapeutic settings
1148:
1009:
216:
inhibitor): FDA-approved in February 2021 for treatment of relapsed or refractory
1711:
5171:
5151:
5136:
5131:
5116:
5074:
5044:
4984:
4954:
4898:
4871:
4744:
4685:
4657:
4647:
4600:
4564:
4480:
4442:
4424:
4419:
4399:
4376:
4347:
4325:
4305:
4295:
4146:
4131:
4111:
3997:
3928:
3914:
3869:
3802:
3797:
3774:
3749:
3717:
3660:
3623:
3600:
3585:
3580:
3565:
2839:
for "UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome" at
591:
447:
421:
was withdrawn by the sponsor when it was no longer expected to lead to approval.
199:
115:
3382:
3219:
for "MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)" at
1341:
1285:
1212:
1056:
5161:
5064:
5059:
5034:
5029:
5019:
5014:
5009:
4979:
4969:
4934:
4929:
4909:
4864:
4852:
4827:
4822:
4812:
4794:
4789:
4779:
4774:
4732:
4720:
4708:
4680:
4667:
4662:
4632:
4595:
4590:
4528:
4523:
4469:
4414:
4366:
4352:
4300:
4287:
4256:
4189:
4178:
4151:
4141:
4136:
4082:
4037:
4032:
3933:
3897:
3829:
3819:
3808:
3792:
3744:
3727:
3703:
3655:
3643:
3595:
3337:
2143:
2126:
1525:
1516:
Blagosklonny MV. Anti-aging: senolytics or gerostatics (unconventional view).
1101:
961:
850:
675:
663:
613:
571:
536:
526:
433:
399:
366:
323:
285:
274:
223:
205:
163:
138:
99:
80:
45:
37:
29:
25:
5176:
5156:
5111:
5101:
5095:
4999:
4944:
4893:
4817:
4807:
4762:
4749:
4690:
4652:
4580:
4518:
4459:
4448:
4404:
4361:
4320:
4314:
4310:
4272:
4199:
4194:
4184:
4156:
4116:
4077:
4052:
4042:
4002:
3648:
3638:
3633:
3628:
3590:
1919:
1902:
1397:
659:
516:
410:
388:
346:
187:
177:
153:
3477:
3439:
3390:
3355:
2915:
2760:
2093:
2018:
1928:
1869:
1814:
1729:
1532:
1503:
1463:
1405:
1359:
1324:
Vanhaesebroeck B, Perry MW, Brown JR, André F, Okkenhaug K (October 2021).
1293:
1258:
1220:
1166:
1109:
1074:
1017:
979:
930:
3058:"Search for phase 2 clinical trials with GSK2636771 on clinicaltrials.gov"
2706:"Search for phase 2 clinical trials with GSK2269557 on clinicaltrials.gov"
2185:"Search for phase 2 clinical trials with Dactolisib on clinicaltrials.gov"
248:) is still ongoing and results are expected for October 2026. The FDA has
5085:
5049:
4989:
4757:
4695:
4475:
4371:
4343:
4022:
3859:
3253:"Search for phase 1 clinical trials with TG100-115 on clinicaltrials.gov"
2815:"Search for phase 2 clinical trials with LY3023414 on clinicaltrials.gov"
2795:"Search for phase 2 clinical trials with SAR245408 on clinicaltrials.gov"
1545:"FDA approves new treatment for adults with relapsed follicular lymphoma"
911:
873:
844:
830:
711:
629:
601:
315:
111:
3233:"Search for phase 1 clinical trials with PWT33597 on clinicaltrials.gov"
2686:"Search for phase 2 clinical trials with YY-20394 on clinicaltrials.gov"
2646:"Search for phase 2 clinical trials with CUDC-907 on clinicaltrials.gov"
2568:"Search for phase 2 clinical trials with GDC-0980 on clinicaltrials.gov"
1133:"Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors"
3978:
3879:
3693:
3554:
3469:
3273:"Search for phase 1 clinical trials with ZSTK474 on clinicaltrials.gov"
2775:"Search for phase 2 clinical trials with IPI-549 on clinicaltrials.gov"
2666:"Search for phase 2 clinical trials with PKI-587 on clinicaltrials.gov"
2608:"Search for phase 2 clinical trials with IPI-549 on clinicaltrials.gov"
2278:"Search for phase 3 clinical trials with CAL-101 on clinicaltrials.gov"
1965:
for "Phase III Copanlisib in Rituximab-refractory iNHL (CHRONOS-2)" at
1649:
1495:
1250:
685:
87:
2930:"Search for phase 2 clinical trials with PX-866 on clinicaltrials.gov"
2588:"Search for phase 2 clinical trials with PQR309 on clinicaltrials.gov"
2376:
for "Dose Optimization Study of Idelalisib in Follicular Lymphoma" at
895:"PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects"
3618:
358:
213:
107:
103:
98:
have a catalytic subunit known as p110, with four types (isoforms) –
628:(codenamed GTPL8918, LY3023414; triple pan-class I PI3K, mTOR, and
3141:"Search for clinical trials with GSK2126458 on clinicaltrials.gov"
893:
Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT (March 2021).
126:
15:
3320:
Zhou H, Yu C, Kong L, Xu X, Yan J, Li Y, et al. (May 2019).
1681:
for "Study of Efficacy of CDZ173 in Patients With APDS/PASLI" at
1635:
This article incorporates text from this source, which is in the
33:
3500:
121:
PI3K inhibitors are also under investigation as treatments for
318:, to cancel their breast cancer study program with buparlisib.
125:, and are used to investigate the role of the PI3K pathway in
1137:
Hematology. American Society of Hematology. Education Program
118:-negative tumors may be more sensitive to PIK3CB inhibitors.
642:. The trial has been terminated due to enrolment challenges.
277:(codenamed BKM120, NVP-BKM120; pan-class I PI3K inhibitor):
3044:
for "AZD8186 and Paclitaxel in Advanced Gastric Cancer" at
391:(codenamed INK1197, IPI-145; PIK3CD and PIK3CG inhibitor):
1386:
The Journal of Pharmacology and Experimental Therapeutics
212:; codenamed TGR-1202, Rp-5264; PIK3CD and casein kinase
1311:"FDA approves Zydelig for three types of blood cancers"
48:
inhibit the PI3K/AKT/mTOR pathway, but not PI3K itself.
1561:. US Food and Drug Administration. September 24, 2018.
1547:. US Food and Drug Administration. September 14, 2017.
228:
1573:"FDA approves first PI3K inhibitor for breast cancer"
394:
The results of the completed pivotal phase III trial
3026:
for "AMG 319 in HPV Positive and Negative HNSCC" at
4886:
4837:
4617:
4610:
4546:
4500:
4433:
4390:
4227:
4212:
4092:
4062:
3987:
3972:
3943:
3839:
3759:
3702:
3685:
3674:
3610:
3563:
3544:
2986:"In Focus: Voxtalisib for CLL and B-Cell Lymphomas"
870:
for inhibitors of AKT and mTOR downstream from PI3K
1313:. US Food and Drug Administration. July 23, 2014.
160:(FL) after at least two prior systemic therapies.
148:; codenamed CAL-101, GS-1101; PIK3CD inhibitor):
377:(RTB-101-204) to prevent clinically symptomatic
295:(HNSCC). Results are expected for December 2022.
226:(codenamed CDZ173; PIK3CD inhibitor, trade name
24:. There are pan-class I PI3K inhibitors such as
857:PI3K inhibitor), mainly used as a research tool
837:PI3K inhibitor), mainly used as a research tool
417:with rituximab + bendamustine in patients with
2298:"Zydelig : EPAR - Scientific conclusions"
1671:
1669:
3512:
3492:Novartis on BEZ235 and BKM120 PI3K inhibitors
8:
3371:Bioorganic & Medicinal Chemistry Letters
1437:
1435:
1429:. News-medical.net. Retrieved on 2010-11-05.
1305:
1303:
991:
989:
240:in a placebo-controlled phase II/III trial (
174:after at least two prior systemic therapies.
1593:"Ukoniq (umbralisib) tablets, for oral use"
1326:"PI3K inhibitors are finally coming of age"
1232:
1230:
899:International Journal of Molecular Sciences
28:, isoform-specific PI3K inhibitors such as
4614:
4224:
3984:
3699:
3682:
3560:
3519:
3505:
3497:
357:compares copanlisib + immunochemotherapy (
232:) was tested as a potential treatment for
3429:
3345:
2905:
2750:
2142:
2083:
1918:
1804:
1719:
1650:"Federal Register :: Request Access"
1477:
1475:
1473:
1349:
1156:
1064:
969:
920:
910:
489:Warm antibody autoimmune hemolytic anemia
1045:Signal Transduction and Targeted Therapy
885:
807:(dual PIK3CA and mTOR inhibitor with IC
2317:
2306:
1379:
1377:
1131:Hanlon A, Brander DM (December 2020).
944:Hoxhaj G, Manning BD (February 2020).
772:(mainly a PIK3CD and PIK3CG inhibitor)
63:(PI3K) enzymes, which are part of the
998:Expert Opinion on Therapeutic Patents
876:, P110δ (PI3K-delta) as a drug target
584:): A phase II trial in patients with
398:comparing duvelisib monotherapy with
288:to paclitaxel alone in patients with
7:
5244:Phosphoinositide 3-kinase inhibitors
1848:placebo-controlled, phase 3 trial".
843:(triple pan-class I PI3K, mTOR, and
53:Phosphoinositide 3-kinase inhibitors
3788:ribonucleotide reductase inhibitors
811:values of 4 nM and 21 nM)
580:(codenamed CUDC-907; PI3K p110 and
3954:Ribonucleotide reductase inhibitor
3910:Ribonucleotide reductase inhibitor
14:
3713:Dihydrofolate reductase inhibitor
3458:Biochemical Society Transactions
1630:
1520:. 2021 Aug 31;12(18):1821-1835.
1484:Biochemical Society Transactions
1239:Biochemical Society Transactions
766:(dual PIK3CA and mTOR inhibitor)
706:is a peptidic prodrug targeting
123:inflammatory respiratory disease
86:There are different classes and
3307:10.1182/blood.V122.21.3067.3067
3091:10.1182/blood.V116.21.1783.1783
2131:Translational Medicine of Aging
723:In early stage clinical trials
523:in patients with breast cancer.
491:(WAIHA) in the phase III trial
424:Similarly, the phase III trial
3850:Thymidylate synthase inhibitor
3740:Thymidylate synthase inhibitor
1330:Nature Reviews. Drug Discovery
1:
3770:Adenosine deaminase inhibitor
3611:Block microtubule disassembly
3422:10.1158/1535-7163.MCT-08-1200
3410:Molecular Cancer Therapeutics
2907:10.1158/1535-7163.MCT-06-0698
2894:Molecular Cancer Therapeutics
2743:10.1158/1078-0432.CCR-14-0947
2076:10.1158/1535-7163.MCT-09-0160
2064:Molecular Cancer Therapeutics
2011:10.1016/S1470-2045(21)00145-5
1862:10.1016/S1470-2045(17)30688-5
1797:10.1016/S1470-2045(17)30376-5
1456:10.1158/0008-5472.CAN-09-2525
1149:10.1182/hematology.2020000119
1010:10.1080/13543776.2021.1924150
586:diffuse large B-cell lymphoma
469:(MCL) in the phase III trial
460:(MZL) in the phase III trial
252:leniolisib on March 24, 2023.
234:activated PI3K delta syndrome
1712:10.1182/blood-2017-08-801191
1616:Food and Drug Administration
1578:Food and Drug Administration
1182:"Zeroing in on PI3K Pathway"
801:(pan-class I PI3K inhibitor)
1654:unblock.federalregister.gov
1201:Current Medicinal Chemistry
827:(mainly a PIK3CD inhibitor)
778:(mainly a PIK3CD inhibitor)
5265:
3383:10.1016/j.bmcl.2010.03.046
1342:10.1038/s41573-021-00209-1
1286:10.1016/j.ctrv.2013.08.006
1213:10.2174/092986709787581905
1057:10.1038/s41392-021-00572-w
506:in the phase II/III trial
257:Under clinical development
5239:Experimental cancer drugs
5189:
5070:Omacetaxine mepesuccinate
4950:Ciltacabtagene autoleucel
4940:Brexucabtagene autoleucel
3338:10.1038/s41388-018-0674-5
2144:10.1016/j.tma.2020.01.002
1526:10.18632/oncotarget.28049
1102:10.1007/s40264-018-0778-4
962:10.1038/s41568-019-0216-7
312:progression-free survival
268:phase III clinical trials
61:phosphoinositide 3-kinase
5122:Talimogene laherparepvec
5055:Nadofaragene firadenovec
5025:Lisocabtagene maraleucel
3974:Topoisomerase inhibitors
3893:DNA polymerase inhibitor
2731:Clinical Cancer Research
1274:Cancer Treatment Reviews
549:phase II clinical trials
478:in the phase III trials
4925:Axicabtagene ciloleucel
3529:chemotherapeutic agents
1398:10.1124/jpet.106.111674
293:squamous cell carcinoma
5107:Sitimagene ceradenovec
5005:Idecabtagene vicleucel
4570:Methyl aminolevulinate
3213:Clinical trial number
3195:Clinical trial number
3177:Clinical trial number
3159:Clinical trial number
3121:Clinical trial number
3103:Clinical trial number
3038:Clinical trial number
3020:Clinical trial number
3002:Clinical trial number
2990:Cancer Therapy Advisor
2966:Clinical trial number
2948:Clinical trial number
2869:Clinical trial number
2851:Clinical trial number
2833:Clinical trial number
2626:Clinical trial number
2547:Clinical trial number
2529:Clinical trial number
2510:Clinical trial number
2478:Clinical trial number
2460:Clinical trial number
2442:Clinical trial number
2424:Clinical trial number
2406:Clinical trial number
2388:Clinical trial number
2370:Clinical trial number
2352:Clinical trial number
2334:Clinical trial number
2316:Cite journal requires
2258:Clinical trial number
2239:Clinical trial number
2221:Clinical trial number
2203:Clinical trial number
2165:Clinical trial number
2106:Clinical trial number
2039:Clinical trial number
1977:Clinical trial number
1959:Clinical trial number
1941:Clinical trial number
1882:Clinical trial number
1827:Clinical trial number
1760:Clinical trial number
1742:Clinical trial number
1675:Clinical trial number
950:Nature Reviews. Cancer
783:Not in clinical trials
458:marginal zone lymphoma
409:comparing duvelisib +
345:compares copanlisib +
284:compares buparlisib +
218:marginal zone lymphoma
133:Approved for treatment
49:
4581:Porphyrin derivatives
4277:Melphalan flufenamide
3924:Hypomethylating agent
3533:antineoplastic agents
2125:Kaeberlein M (2020).
1920:10.1093/annonc/mdw562
1180:Flanagan (Dec 2008).
868:PI3K/AKT/mTOR pathway
662:(codenamed PX-866; a
298:The phase III trials
65:PI3K/AKT/mTOR pathway
22:PI3K/AKT/mTOR pathway
19:
4910:Asparagine depleters
4839:Receptor antagonists
4753:+abiraterone acetate
1999:The Lancet. Oncology
1850:The Lancet. Oncology
1785:The Lancet. Oncology
912:10.3390/ijms22073464
650:renal cell carcinoma
467:Mantle cell lymphoma
419:non-Hodgkin lymphoma
405:The phase III trial
353:The phase III trial
341:The phase III trial
328:non-Hodgkin lymphoma
280:The phase III trial
4960:Denileukin diftitox
4860:Retinoid X receptor
4560:Aminolevulinic acid
4382:Triethylenemelamine
4214:Crosslinking of DNA
3945:Deoxyribonucleotide
3884:+gimeracil/oteracil
680:follicular lymphoma
564:(codenamed PQR309;
454:Follicular lymphoma
379:respiratory illness
172:follicular lymphoma
158:follicular lymphoma
36:inhibitors such as
5216:Never to phase III
4018:Etirinotecan pegol
3470:10.1042/BST0370615
3221:ClinicalTrials.gov
3203:ClinicalTrials.gov
3185:ClinicalTrials.gov
3167:ClinicalTrials.gov
3129:ClinicalTrials.gov
3111:ClinicalTrials.gov
3046:ClinicalTrials.gov
3028:ClinicalTrials.gov
3010:ClinicalTrials.gov
2974:ClinicalTrials.gov
2956:ClinicalTrials.gov
2877:ClinicalTrials.gov
2859:ClinicalTrials.gov
2841:ClinicalTrials.gov
2634:ClinicalTrials.gov
2556:ClinicalTrials.gov
2537:ClinicalTrials.gov
2519:ClinicalTrials.gov
2486:ClinicalTrials.gov
2468:ClinicalTrials.gov
2450:ClinicalTrials.gov
2432:ClinicalTrials.gov
2414:ClinicalTrials.gov
2396:ClinicalTrials.gov
2378:ClinicalTrials.gov
2360:ClinicalTrials.gov
2342:ClinicalTrials.gov
2266:ClinicalTrials.gov
2248:ClinicalTrials.gov
2229:ClinicalTrials.gov
2211:ClinicalTrials.gov
2173:ClinicalTrials.gov
2114:ClinicalTrials.gov
2047:ClinicalTrials.gov
1985:ClinicalTrials.gov
1967:ClinicalTrials.gov
1949:ClinicalTrials.gov
1907:Annals of Oncology
1890:ClinicalTrials.gov
1836:ClinicalTrials.gov
1768:ClinicalTrials.gov
1750:ClinicalTrials.gov
1683:ClinicalTrials.gov
1598:. TG Therapeutics.
1496:10.1042/BST0350253
1251:10.1042/BST0370265
874:P110δ#Pharmacology
748:(PIK3CD inhibitor)
708:integrin receptors
654:endometrial cancer
512:Kazia PR July 2024
371:placebo-controlled
50:
5226:
5225:
5185:
5184:
5142:Tigilanol tiglate
4619:Enzyme inhibitors
4542:
4541:
4538:
4537:
4238:Nitrogen mustards
4208:
4207:
3968:
3967:
3670:
3669:
3464:(Pt 4): 615–626.
3332:(18): 3371–3386.
2992:. March 27, 2018.
1706:(21): 2307–2316.
1620:. 5 February 2021
1490:(Pt 2): 253–256.
1245:(Pt 1): 265–272.
710:that converts to
5256:
5249:Targeted therapy
5147:Tisagenlecleucel
4904:Arsenic trioxide
4615:
4548:Photosensitizers
4339:Alkyl sulfonates
4253:Cyclophosphamide
4225:
4164:Anthracenediones
3985:
3959:Hydroxycarbamide
3700:
3683:
3561:
3521:
3514:
3507:
3498:
3481:
3444:
3443:
3433:
3416:(7): 1725–1738.
3401:
3395:
3394:
3377:(8): 2408–2411.
3366:
3360:
3359:
3349:
3317:
3311:
3310:
3289:
3283:
3282:
3280:
3279:
3269:
3263:
3262:
3260:
3259:
3249:
3243:
3242:
3240:
3239:
3229:
3223:
3211:
3205:
3193:
3187:
3175:
3169:
3157:
3151:
3150:
3148:
3147:
3137:
3131:
3119:
3113:
3101:
3095:
3094:
3074:
3068:
3067:
3065:
3064:
3054:
3048:
3036:
3030:
3018:
3012:
3000:
2994:
2993:
2982:
2976:
2964:
2958:
2946:
2940:
2939:
2937:
2936:
2926:
2920:
2919:
2909:
2900:(9): 2505–2514.
2885:
2879:
2867:
2861:
2849:
2843:
2831:
2825:
2824:
2822:
2821:
2811:
2805:
2804:
2802:
2801:
2791:
2785:
2784:
2782:
2781:
2771:
2765:
2764:
2754:
2722:
2716:
2715:
2713:
2712:
2702:
2696:
2695:
2693:
2692:
2682:
2676:
2675:
2673:
2672:
2662:
2656:
2655:
2653:
2652:
2642:
2636:
2624:
2618:
2617:
2615:
2614:
2604:
2598:
2597:
2595:
2594:
2584:
2578:
2577:
2575:
2574:
2564:
2558:
2545:
2539:
2527:
2521:
2508:
2502:
2501:
2494:
2488:
2476:
2470:
2458:
2452:
2440:
2434:
2422:
2416:
2404:
2398:
2386:
2380:
2368:
2362:
2350:
2344:
2332:
2326:
2325:
2319:
2314:
2312:
2304:
2302:
2294:
2288:
2287:
2285:
2284:
2274:
2268:
2256:
2250:
2237:
2231:
2219:
2213:
2201:
2195:
2194:
2192:
2191:
2181:
2175:
2163:
2157:
2156:
2146:
2122:
2116:
2104:
2098:
2097:
2087:
2070:(8): 2204–2210.
2055:
2049:
2037:
2031:
2030:
1993:
1987:
1975:
1969:
1957:
1951:
1939:
1933:
1932:
1922:
1898:
1892:
1880:
1874:
1873:
1844:
1838:
1825:
1819:
1818:
1808:
1776:
1770:
1758:
1752:
1740:
1734:
1733:
1723:
1691:
1685:
1673:
1664:
1663:
1661:
1660:
1646:
1640:
1634:
1633:
1629:
1627:
1625:
1606:
1600:
1599:
1597:
1589:
1583:
1582:
1569:
1563:
1562:
1555:
1549:
1548:
1541:
1535:
1514:
1508:
1507:
1479:
1468:
1467:
1450:(3): 1164–1172.
1439:
1430:
1424:
1418:
1417:
1381:
1372:
1371:
1353:
1321:
1315:
1314:
1307:
1298:
1297:
1269:
1263:
1262:
1234:
1225:
1224:
1196:
1190:
1189:
1184:. Archived from
1177:
1171:
1170:
1160:
1128:
1122:
1121:
1085:
1079:
1078:
1068:
1036:
1030:
1029:
993:
984:
983:
973:
941:
935:
934:
924:
914:
890:
640:Sjögren syndrome
373:phase III trial
74:targeted therapy
32:, and dual PI3K/
5264:
5263:
5259:
5258:
5257:
5255:
5254:
5253:
5229:
5228:
5227:
5222:
5221:
5206:Clinical trials
5181:
4887:Other/ungrouped
4882:
4833:
4606:
4586:Porfimer sodium
4534:
4496:
4429:
4386:
4216:
4204:
4088:
4058:
3976:
3964:
3939:
3835:
3755:
3691:
3689:antimetabolites
3687:
3686:DNA precursors/
3678:
3676:DNA replication
3666:
3606:
3576:Vinca alkaloids
3552:
3540:
3525:
3488:
3455:
3452:
3450:Further reading
3447:
3403:
3402:
3398:
3368:
3367:
3363:
3319:
3318:
3314:
3291:
3290:
3286:
3277:
3275:
3271:
3270:
3266:
3257:
3255:
3251:
3250:
3246:
3237:
3235:
3231:
3230:
3226:
3212:
3208:
3194:
3190:
3176:
3172:
3158:
3154:
3145:
3143:
3139:
3138:
3134:
3120:
3116:
3102:
3098:
3076:
3075:
3071:
3062:
3060:
3056:
3055:
3051:
3037:
3033:
3019:
3015:
3001:
2997:
2984:
2983:
2979:
2965:
2961:
2947:
2943:
2934:
2932:
2928:
2927:
2923:
2887:
2886:
2882:
2868:
2864:
2850:
2846:
2832:
2828:
2819:
2817:
2813:
2812:
2808:
2799:
2797:
2793:
2792:
2788:
2779:
2777:
2773:
2772:
2768:
2724:
2723:
2719:
2710:
2708:
2704:
2703:
2699:
2690:
2688:
2684:
2683:
2679:
2670:
2668:
2664:
2663:
2659:
2650:
2648:
2644:
2643:
2639:
2625:
2621:
2612:
2610:
2606:
2605:
2601:
2592:
2590:
2586:
2585:
2581:
2572:
2570:
2566:
2565:
2561:
2546:
2542:
2528:
2524:
2509:
2505:
2496:
2495:
2491:
2477:
2473:
2459:
2455:
2441:
2437:
2423:
2419:
2405:
2401:
2387:
2383:
2369:
2365:
2351:
2347:
2333:
2329:
2315:
2305:
2300:
2296:
2295:
2291:
2282:
2280:
2276:
2275:
2271:
2257:
2253:
2238:
2234:
2220:
2216:
2202:
2198:
2189:
2187:
2183:
2182:
2178:
2164:
2160:
2124:
2123:
2119:
2105:
2101:
2057:
2056:
2052:
2038:
2034:
1995:
1994:
1990:
1976:
1972:
1958:
1954:
1940:
1936:
1900:
1899:
1895:
1881:
1877:
1846:
1845:
1841:
1826:
1822:
1778:
1777:
1773:
1759:
1755:
1741:
1737:
1693:
1692:
1688:
1674:
1667:
1658:
1656:
1648:
1647:
1643:
1631:
1623:
1621:
1608:
1607:
1603:
1595:
1591:
1590:
1586:
1571:
1570:
1566:
1557:
1556:
1552:
1543:
1542:
1538:
1515:
1511:
1481:
1480:
1471:
1444:Cancer Research
1441:
1440:
1433:
1425:
1421:
1383:
1382:
1375:
1336:(10): 741–769.
1323:
1322:
1318:
1309:
1308:
1301:
1271:
1270:
1266:
1236:
1235:
1228:
1198:
1197:
1193:
1179:
1178:
1174:
1130:
1129:
1125:
1087:
1086:
1082:
1038:
1037:
1033:
1004:(10): 877–892.
995:
994:
987:
943:
942:
938:
892:
891:
887:
883:
864:
821:PI3K inhibitor)
810:
791:(dual PI3K and
785:
721:
264:
259:
135:
57:PI3K inhibitors
12:
11:
5:
5262:
5260:
5252:
5251:
5246:
5241:
5231:
5230:
5224:
5223:
5220:
5219:
5218:
5217:
5214:
5203:
5197:
5191:
5190:
5187:
5186:
5183:
5182:
5180:
5179:
5174:
5169:
5164:
5159:
5154:
5149:
5144:
5139:
5134:
5129:
5124:
5119:
5114:
5109:
5104:
5099:
5093:
5082:
5077:
5072:
5067:
5062:
5057:
5052:
5047:
5042:
5037:
5032:
5027:
5022:
5017:
5012:
5007:
5002:
4997:
4992:
4987:
4982:
4977:
4972:
4967:
4962:
4957:
4952:
4947:
4942:
4937:
4932:
4927:
4922:
4906:
4901:
4896:
4890:
4888:
4884:
4883:
4881:
4880:
4868:
4856:
4843:
4841:
4835:
4834:
4832:
4831:
4825:
4820:
4815:
4810:
4798:
4792:
4787:
4782:
4777:
4766:
4760:
4755:
4747:
4740:PARP inhibitor
4736:
4724:
4712:
4700:
4699:
4698:
4693:
4688:
4683:
4671:
4665:
4660:
4655:
4650:
4636:
4623:
4621:
4612:
4608:
4607:
4605:
4604:
4598:
4593:
4588:
4577:
4572:
4567:
4562:
4556:
4554:
4544:
4543:
4540:
4539:
4536:
4535:
4533:
4532:
4526:
4521:
4516:
4506:
4504:
4498:
4497:
4495:
4494:
4488:
4483:
4472:
4467:
4462:
4457:
4445:
4439:
4437:
4431:
4430:
4428:
4427:
4422:
4417:
4412:
4407:
4402:
4396:
4394:
4392:Platinum-based
4388:
4387:
4385:
4384:
4379:
4374:
4369:
4357:
4356:
4350:
4334:
4333:
4328:
4323:
4318:
4308:
4303:
4291:
4290:
4285:
4280:
4270:
4265:
4259:
4250:
4245:
4233:
4231:
4222:
4210:
4209:
4206:
4205:
4203:
4202:
4197:
4192:
4187:
4182:
4176:
4171:
4160:
4154:
4149:
4144:
4139:
4134:
4129:
4119:
4114:
4107:Anthracyclines
4102:
4100:
4090:
4089:
4087:
4086:
4080:
4068:
4066:
4060:
4059:
4057:
4056:
4050:
4045:
4040:
4035:
4030:
4025:
4020:
4015:
4010:
4005:
3993:
3991:
3982:
3970:
3969:
3966:
3965:
3963:
3962:
3949:
3947:
3941:
3940:
3938:
3937:
3931:
3919:
3918:
3905:
3904:
3888:
3887:
3877:
3872:
3867:
3862:
3857:
3845:
3843:
3837:
3836:
3834:
3833:
3827:
3825:Mercaptopurine
3816:
3811:
3806:
3800:
3795:
3779:
3778:
3765:
3763:
3757:
3756:
3754:
3753:
3747:
3736:
3730:
3725:
3720:
3708:
3706:
3697:
3680:
3672:
3671:
3668:
3667:
3665:
3664:
3652:
3646:
3641:
3636:
3631:
3626:
3614:
3612:
3608:
3607:
3605:
3604:
3598:
3593:
3588:
3583:
3571:
3569:
3558:
3542:
3541:
3527:Intracellular
3526:
3524:
3523:
3516:
3509:
3501:
3495:
3494:
3487:
3486:External links
3484:
3483:
3482:
3451:
3448:
3446:
3445:
3396:
3361:
3312:
3284:
3264:
3244:
3224:
3206:
3188:
3170:
3152:
3132:
3114:
3096:
3069:
3049:
3031:
3013:
2995:
2977:
2959:
2941:
2921:
2880:
2862:
2844:
2826:
2806:
2786:
2766:
2717:
2697:
2677:
2657:
2637:
2619:
2599:
2579:
2559:
2540:
2522:
2503:
2489:
2471:
2453:
2435:
2417:
2399:
2381:
2363:
2345:
2327:
2318:|journal=
2289:
2269:
2251:
2232:
2214:
2196:
2176:
2158:
2117:
2099:
2050:
2032:
2005:(5): 678–689.
1988:
1970:
1952:
1934:
1913:(2): 313–320.
1893:
1875:
1839:
1820:
1791:(7): 904–916.
1771:
1753:
1735:
1686:
1665:
1641:
1601:
1584:
1564:
1550:
1536:
1509:
1469:
1431:
1419:
1373:
1316:
1299:
1280:(3): 445–456.
1264:
1226:
1207:(8): 916–930.
1191:
1188:on 2013-01-24.
1172:
1143:(1): 346–356.
1123:
1096:(2): 247–262.
1080:
1031:
985:
936:
884:
882:
879:
878:
877:
871:
863:
860:
859:
858:
848:
838:
828:
822:
812:
808:
802:
796:
784:
781:
780:
779:
773:
767:
761:
755:
749:
743:
737:
731:
720:
717:
716:
715:
701:
695:
689:
683:
673:
667:
657:
643:
633:
623:
617:
611:
605:
595:
589:
582:HDAC inhibitor
575:
569:
566:brain-permeant
559:
545:
544:
534:
524:
514:
497:
496:
495:
486:
473:
464:
445:
441:GS-US-312-0116
431:
430:
429:
422:
403:
386:
364:
363:
362:
351:
339:
321:
320:
319:
296:
263:
260:
258:
255:
254:
253:
221:
203:
185:
175:
161:
134:
131:
69:signal pathway
13:
10:
9:
6:
4:
3:
2:
5261:
5250:
5247:
5245:
5242:
5240:
5237:
5236:
5234:
5215:
5213:
5210:
5209:
5207:
5204:
5201:
5198:
5196:
5193:
5192:
5188:
5178:
5175:
5173:
5170:
5168:
5165:
5163:
5160:
5158:
5155:
5153:
5150:
5148:
5145:
5143:
5140:
5138:
5135:
5133:
5130:
5128:
5125:
5123:
5120:
5118:
5115:
5113:
5110:
5108:
5105:
5103:
5100:
5097:
5094:
5092:
5088:
5087:
5083:
5081:
5080:Tabelecleucel
5078:
5076:
5073:
5071:
5068:
5066:
5063:
5061:
5058:
5056:
5053:
5051:
5048:
5046:
5043:
5041:
5040:Lurbinectedin
5038:
5036:
5033:
5031:
5028:
5026:
5023:
5021:
5018:
5016:
5013:
5011:
5008:
5006:
5003:
5001:
4998:
4996:
4993:
4991:
4988:
4986:
4983:
4981:
4978:
4976:
4973:
4971:
4968:
4966:
4963:
4961:
4958:
4956:
4953:
4951:
4948:
4946:
4943:
4941:
4938:
4936:
4933:
4931:
4928:
4926:
4923:
4920:
4916:
4912:
4911:
4907:
4905:
4902:
4900:
4897:
4895:
4892:
4891:
4889:
4885:
4878:
4874:
4873:
4869:
4866:
4862:
4861:
4857:
4854:
4850:
4849:
4845:
4844:
4842:
4840:
4836:
4829:
4826:
4824:
4821:
4819:
4816:
4814:
4811:
4809:
4805:
4803:
4799:
4796:
4793:
4791:
4788:
4786:
4783:
4781:
4778:
4776:
4772:
4771:
4767:
4764:
4761:
4759:
4756:
4754:
4751:
4748:
4746:
4742:
4741:
4737:
4734:
4730:
4729:
4725:
4722:
4718:
4717:
4713:
4710:
4706:
4705:
4701:
4697:
4694:
4692:
4689:
4687:
4684:
4682:
4679:
4678:
4677:
4676:
4672:
4669:
4666:
4664:
4661:
4659:
4656:
4654:
4651:
4649:
4645:
4644:
4641:
4637:
4634:
4630:
4629:
4625:
4624:
4622:
4620:
4616:
4613:
4609:
4602:
4599:
4597:
4594:
4592:
4589:
4587:
4583:
4582:
4578:
4576:
4573:
4571:
4568:
4566:
4563:
4561:
4558:
4557:
4555:
4553:
4549:
4545:
4530:
4527:
4525:
4522:
4520:
4517:
4515:
4511:
4508:
4507:
4505:
4503:
4502:Intercalation
4499:
4492:
4489:
4487:
4484:
4482:
4478:
4477:
4473:
4471:
4468:
4466:
4463:
4461:
4458:
4455:
4451:
4450:
4446:
4444:
4441:
4440:
4438:
4436:
4432:
4426:
4423:
4421:
4418:
4416:
4413:
4411:
4410:Dicycloplatin
4408:
4406:
4403:
4401:
4398:
4397:
4395:
4393:
4389:
4383:
4380:
4378:
4375:
4373:
4370:
4368:
4365:
4363:
4359:
4358:
4354:
4351:
4349:
4345:
4342:
4340:
4336:
4335:
4332:
4329:
4327:
4324:
4322:
4319:
4316:
4312:
4309:
4307:
4304:
4302:
4299:
4297:
4293:
4292:
4289:
4286:
4284:
4283:Prednimustine
4281:
4278:
4274:
4271:
4269:
4266:
4263:
4260:
4258:
4254:
4251:
4249:
4246:
4244:
4241:
4239:
4235:
4234:
4232:
4230:
4226:
4223:
4220:
4215:
4211:
4201:
4198:
4196:
4193:
4191:
4188:
4186:
4183:
4180:
4177:
4175:
4172:
4170:
4166:
4165:
4161:
4158:
4155:
4153:
4150:
4148:
4145:
4143:
4140:
4138:
4135:
4133:
4130:
4127:
4123:
4120:
4118:
4115:
4113:
4109:
4108:
4104:
4103:
4101:
4099:
4098:Intercalation
4095:
4091:
4084:
4081:
4079:
4075:
4074:
4070:
4069:
4067:
4065:
4061:
4054:
4051:
4049:
4046:
4044:
4041:
4039:
4036:
4034:
4031:
4029:
4026:
4024:
4021:
4019:
4016:
4014:
4011:
4009:
4006:
4004:
4000:
3999:
3995:
3994:
3992:
3990:
3986:
3983:
3980:
3975:
3971:
3960:
3956:
3955:
3951:
3950:
3948:
3946:
3942:
3935:
3932:
3930:
3926:
3925:
3921:
3920:
3916:
3912:
3911:
3907:
3906:
3902:
3901:+daunorubicin
3899:
3895:
3894:
3890:
3889:
3885:
3881:
3878:
3876:
3873:
3871:
3868:
3866:
3865:Doxifluridine
3863:
3861:
3858:
3856:
3852:
3851:
3847:
3846:
3844:
3842:
3838:
3831:
3828:
3826:
3822:
3821:
3817:
3815:
3814:Rabacfosadine
3812:
3810:
3807:
3804:
3801:
3799:
3796:
3794:
3790:
3789:
3785:
3781:
3780:
3776:
3772:
3771:
3767:
3766:
3764:
3762:
3758:
3751:
3748:
3746:
3742:
3741:
3737:
3734:
3731:
3729:
3726:
3724:
3721:
3719:
3715:
3714:
3710:
3709:
3707:
3705:
3701:
3698:
3695:
3690:
3684:
3681:
3677:
3673:
3662:
3658:
3657:
3653:
3650:
3647:
3645:
3642:
3640:
3637:
3635:
3632:
3630:
3627:
3625:
3621:
3620:
3616:
3615:
3613:
3609:
3602:
3599:
3597:
3594:
3592:
3589:
3587:
3584:
3582:
3578:
3577:
3573:
3572:
3570:
3567:
3562:
3559:
3556:
3551:
3547:
3543:
3538:
3534:
3530:
3522:
3517:
3515:
3510:
3508:
3503:
3502:
3499:
3493:
3490:
3489:
3485:
3479:
3475:
3471:
3467:
3463:
3459:
3454:
3453:
3449:
3441:
3437:
3432:
3427:
3423:
3419:
3415:
3411:
3407:
3400:
3397:
3392:
3388:
3384:
3380:
3376:
3372:
3365:
3362:
3357:
3353:
3348:
3343:
3339:
3335:
3331:
3327:
3323:
3316:
3313:
3308:
3304:
3300:
3296:
3288:
3285:
3274:
3268:
3265:
3254:
3248:
3245:
3234:
3228:
3225:
3222:
3218:
3217:
3210:
3207:
3204:
3200:
3199:
3192:
3189:
3186:
3182:
3181:
3174:
3171:
3168:
3164:
3163:
3156:
3153:
3142:
3136:
3133:
3130:
3126:
3125:
3118:
3115:
3112:
3108:
3107:
3100:
3097:
3092:
3088:
3084:
3080:
3073:
3070:
3059:
3053:
3050:
3047:
3043:
3042:
3035:
3032:
3029:
3025:
3024:
3017:
3014:
3011:
3007:
3006:
2999:
2996:
2991:
2987:
2981:
2978:
2975:
2971:
2970:
2963:
2960:
2957:
2953:
2952:
2945:
2942:
2931:
2925:
2922:
2917:
2913:
2908:
2903:
2899:
2895:
2891:
2884:
2881:
2878:
2874:
2873:
2866:
2863:
2860:
2856:
2855:
2848:
2845:
2842:
2838:
2837:
2830:
2827:
2816:
2810:
2807:
2796:
2790:
2787:
2776:
2770:
2767:
2762:
2758:
2753:
2748:
2744:
2740:
2736:
2732:
2728:
2721:
2718:
2707:
2701:
2698:
2687:
2681:
2678:
2667:
2661:
2658:
2647:
2641:
2638:
2635:
2631:
2630:
2623:
2620:
2609:
2603:
2600:
2589:
2583:
2580:
2569:
2563:
2560:
2557:
2552:
2551:
2544:
2541:
2538:
2534:
2533:
2526:
2523:
2520:
2515:
2514:
2507:
2504:
2499:
2493:
2490:
2487:
2483:
2482:
2475:
2472:
2469:
2465:
2464:
2457:
2454:
2451:
2447:
2446:
2439:
2436:
2433:
2429:
2428:
2421:
2418:
2415:
2411:
2410:
2403:
2400:
2397:
2393:
2392:
2385:
2382:
2379:
2375:
2374:
2367:
2364:
2361:
2357:
2356:
2349:
2346:
2343:
2339:
2338:
2331:
2328:
2323:
2310:
2303:. 2016-11-21.
2299:
2293:
2290:
2279:
2273:
2270:
2267:
2263:
2262:
2255:
2252:
2249:
2244:
2243:
2236:
2233:
2230:
2226:
2225:
2218:
2215:
2212:
2208:
2207:
2200:
2197:
2186:
2180:
2177:
2174:
2170:
2169:
2162:
2159:
2154:
2150:
2145:
2140:
2136:
2132:
2128:
2121:
2118:
2115:
2111:
2110:
2103:
2100:
2095:
2091:
2086:
2081:
2077:
2073:
2069:
2065:
2061:
2054:
2051:
2048:
2044:
2043:
2036:
2033:
2028:
2024:
2020:
2016:
2012:
2008:
2004:
2000:
1992:
1989:
1986:
1982:
1981:
1974:
1971:
1968:
1964:
1963:
1956:
1953:
1950:
1946:
1945:
1938:
1935:
1930:
1926:
1921:
1916:
1912:
1908:
1904:
1897:
1894:
1891:
1887:
1886:
1879:
1876:
1871:
1867:
1863:
1859:
1856:(1): 87–100.
1855:
1851:
1843:
1840:
1837:
1832:
1831:
1824:
1821:
1816:
1812:
1807:
1802:
1798:
1794:
1790:
1786:
1782:
1775:
1772:
1769:
1765:
1764:
1757:
1754:
1751:
1747:
1746:
1739:
1736:
1731:
1727:
1722:
1717:
1713:
1709:
1705:
1701:
1697:
1690:
1687:
1684:
1680:
1679:
1672:
1670:
1666:
1655:
1651:
1645:
1642:
1638:
1637:public domain
1619:
1617:
1611:
1605:
1602:
1594:
1588:
1585:
1581:. 2019-05-24.
1580:
1579:
1574:
1568:
1565:
1560:
1554:
1551:
1546:
1540:
1537:
1534:
1530:
1527:
1523:
1519:
1513:
1510:
1505:
1501:
1497:
1493:
1489:
1485:
1478:
1476:
1474:
1470:
1465:
1461:
1457:
1453:
1449:
1445:
1438:
1436:
1432:
1428:
1423:
1420:
1415:
1411:
1407:
1403:
1399:
1395:
1391:
1387:
1380:
1378:
1374:
1369:
1365:
1361:
1357:
1352:
1347:
1343:
1339:
1335:
1331:
1327:
1320:
1317:
1312:
1306:
1304:
1300:
1295:
1291:
1287:
1283:
1279:
1275:
1268:
1265:
1260:
1256:
1252:
1248:
1244:
1240:
1233:
1231:
1227:
1222:
1218:
1214:
1210:
1206:
1202:
1195:
1192:
1187:
1183:
1176:
1173:
1168:
1164:
1159:
1154:
1150:
1146:
1142:
1138:
1134:
1127:
1124:
1119:
1115:
1111:
1107:
1103:
1099:
1095:
1091:
1084:
1081:
1076:
1072:
1067:
1062:
1058:
1054:
1050:
1046:
1042:
1035:
1032:
1027:
1023:
1019:
1015:
1011:
1007:
1003:
999:
992:
990:
986:
981:
977:
972:
967:
963:
959:
955:
951:
947:
940:
937:
932:
928:
923:
918:
913:
908:
904:
900:
896:
889:
886:
880:
875:
872:
869:
866:
865:
861:
856:
852:
849:
846:
842:
839:
836:
832:
829:
826:
823:
820:
816:
813:
806:
803:
800:
797:
794:
790:
787:
786:
782:
777:
774:
771:
768:
765:
762:
759:
756:
753:
750:
747:
744:
741:
738:
735:
732:
729:
726:
725:
724:
718:
713:
709:
705:
702:
699:
696:
693:
690:
687:
684:
681:
677:
674:
671:
668:
665:
661:
658:
655:
651:
647:
644:
641:
637:
634:
631:
627:
624:
621:
618:
615:
612:
609:
606:
603:
599:
596:
593:
590:
587:
583:
579:
576:
573:
570:
567:
563:
560:
557:
554:
553:
552:
550:
542:
538:
535:
532:
528:
525:
522:
518:
515:
513:
509:
505:
501:
498:
494:
490:
487:
485:
481:
477:
476:Myelofibrosis
474:
472:
468:
465:
463:
459:
455:
452:
451:
449:
446:
442:
439:
438:pivotal trial
435:
432:
427:
423:
420:
416:
412:
408:
404:
401:
397:
393:
392:
390:
387:
384:
380:
376:
372:
368:
365:
360:
356:
352:
348:
344:
340:
336:
332:
331:
329:
325:
322:
317:
313:
309:
305:
301:
297:
294:
291:
290:head and neck
287:
283:
279:
278:
276:
273:
272:
271:
269:
261:
256:
251:
247:
243:
239:
238:PASLI disease
235:
231:
230:
225:
222:
219:
215:
211:
207:
204:
201:
197:
193:
190:(trade names
189:
186:
183:
179:
176:
173:
169:
165:
162:
159:
155:
151:
147:
144:
140:
137:
136:
132:
130:
128:
124:
119:
117:
113:
110:(PIK3CG) and
109:
105:
101:
97:
96:Class 1 PI3Ks
93:
89:
84:
82:
77:
75:
70:
66:
62:
58:
54:
47:
43:
39:
35:
31:
27:
23:
18:
5127:Tazemetostat
5091:Alitretinoin
5084:
4995:Estramustine
4975:Elsamitrucin
4965:Eflornithine
4919:Pegaspargase
4915:Asparaginase
4908:
4877:Testolactone
4870:
4858:
4846:
4801:
4800:
4785:Panobinostat
4768:
4738:
4726:
4714:
4702:
4673:
4638:
4626:
4579:
4575:Padeliporfin
4514:Dactinomycin
4510:Streptomyces
4491:Temozolomide
4486:Mitozolomide
4474:
4465:Mitobronitol
4454:Procarbazine
4447:
4435:Nonclassical
4360:
4337:
4331:Streptozocin
4296:Nitrosoureas
4294:
4268:Chlorambucil
4262:Trofosfamide
4248:Chlormethine
4243:Bendamustine
4236:
4174:Mitoxantrone
4169:Losoxantrone
4162:
4122:Daunorubicin
4105:
4071:
4008:Camptothecin
3996:
3952:
3922:
3908:
3891:
3875:Fluorouracil
3855:Capecitabine
3848:
3818:
3782:
3768:
3738:
3733:Pralatrexate
3723:Methotrexate
3711:
3654:
3617:
3574:
3461:
3457:
3413:
3409:
3399:
3374:
3370:
3364:
3329:
3325:
3315:
3301:(21): 3067.
3298:
3294:
3287:
3276:. Retrieved
3267:
3256:. Retrieved
3247:
3236:. Retrieved
3227:
3214:
3209:
3196:
3191:
3178:
3173:
3160:
3155:
3144:. Retrieved
3135:
3122:
3117:
3104:
3099:
3085:(21): 1783.
3082:
3078:
3072:
3061:. Retrieved
3052:
3039:
3034:
3021:
3016:
3003:
2998:
2989:
2980:
2967:
2962:
2949:
2944:
2933:. Retrieved
2924:
2897:
2893:
2883:
2870:
2865:
2852:
2847:
2834:
2829:
2818:. Retrieved
2809:
2798:. Retrieved
2789:
2778:. Retrieved
2769:
2737:(1): 77–86.
2734:
2730:
2720:
2709:. Retrieved
2700:
2689:. Retrieved
2680:
2669:. Retrieved
2660:
2649:. Retrieved
2640:
2627:
2622:
2611:. Retrieved
2602:
2591:. Retrieved
2582:
2571:. Retrieved
2562:
2548:
2543:
2530:
2525:
2511:
2506:
2492:
2479:
2474:
2461:
2456:
2443:
2438:
2425:
2420:
2407:
2402:
2389:
2384:
2371:
2366:
2353:
2348:
2335:
2330:
2309:cite journal
2292:
2281:. Retrieved
2272:
2259:
2254:
2240:
2235:
2222:
2217:
2204:
2199:
2188:. Retrieved
2179:
2166:
2161:
2134:
2130:
2120:
2107:
2102:
2067:
2063:
2053:
2040:
2035:
2002:
1998:
1991:
1978:
1973:
1960:
1955:
1942:
1937:
1910:
1906:
1896:
1883:
1878:
1853:
1849:
1842:
1828:
1823:
1788:
1784:
1774:
1761:
1756:
1743:
1738:
1703:
1699:
1689:
1676:
1657:. Retrieved
1653:
1644:
1622:. Retrieved
1613:
1604:
1587:
1576:
1567:
1553:
1539:
1517:
1512:
1487:
1483:
1447:
1443:
1422:
1389:
1385:
1333:
1329:
1319:
1277:
1273:
1267:
1242:
1238:
1204:
1200:
1194:
1186:the original
1175:
1140:
1136:
1126:
1093:
1089:
1083:
1048:
1044:
1034:
1001:
997:
956:(2): 74–88.
953:
949:
939:
902:
898:
888:
855:irreversible
854:
834:
819:irreversible
818:
722:
578:Fimepinostat
546:
540:
530:
520:
507:
504:glioblastoma
492:
483:
479:
470:
461:
440:
425:
415:bendamustine
406:
395:
382:
374:
354:
342:
334:
307:
303:
299:
281:
265:
245:
241:
227:
209:
208:(trade name
195:
191:
181:
180:(trade name
167:
166:(trade name
145:
120:
85:
78:
56:
52:
51:
42:fimepinostat
40:. Note that
5202:from market
5172:Vorasidenib
5152:Trabectedin
5137:Tiazofurine
5132:Tebentafusp
5117:Tagraxofusp
5075:Plitidepsin
5045:Mitoguazone
4985:Epacadostat
4955:Demecolcine
4899:Aflibercept
4872:Sex steroid
4745:Fuzuloparib
4686:Carfilzomib
4658:Palbociclib
4648:Abemaciclib
4601:Verteporfin
4565:Efaproxiral
4481:Dacarbazine
4443:Altretamine
4425:Satraplatin
4420:Oxaliplatin
4400:Carboplatin
4377:Triaziquone
4348:Mannosulfan
4326:Ranimustine
4306:Fotemustine
4147:Pirarubicin
4132:Doxorubicin
4126:+cytarabine
4112:Aclarubicin
4073:Podophyllum
3998:Camptotheca
3929:Azacitidine
3915:Gemcitabine
3870:Floxuridine
3803:Fludarabine
3798:Clofarabine
3784:Halogenated
3775:Pentostatin
3750:Raltitrexed
3718:Aminopterin
3661:Ixabepilone
3656:Epothilones
3624:Cabazitaxel
3601:Vinorelbine
3586:Vincristine
3581:Vinblastine
3566:microtubule
3216:NCT04495621
3198:NCT00695448
3180:NCT01066611
3162:NCT02260661
3124:NCT01705847
3106:NCT02644122
3041:NCT04001569
3023:NCT02540928
3005:NCT01403636
2969:NCT03711578
2951:NCT04204057
2872:NCT02725268
2854:NCT02724020
2836:NCT02610543
2629:NCT02674750
2550:NCT04191499
2532:NCT04745832
2513:NCT02340221
2481:NCT03970447
2463:NCT05073458
2445:NCT04551066
2427:NCT04551053
2409:NCT04849715
2391:NCT04796922
2373:NCT02536300
2355:NCT04666038
2337:NCT02970318
2261:NCT02204982
2242:NCT02576275
2224:NCT02049515
2206:NCT02004522
2168:NCT04139915
2109:NCT04668352
2042:NCT02626455
1980:NCT02367040
1962:NCT02369016
1944:NCT01572727
1885:NCT01633060
1830:NCT01610284
1763:NCT04338399
1745:NCT02859727
1678:NCT02435173
1090:Drug Safety
905:(7): 3464.
815:Hibiscone C
719:Early stage
646:Serabelisib
636:Seletalisib
626:Samotolisib
620:Pilaralisib
608:Nemiralisib
598:Linperlisib
592:Gedatolisib
562:Bimiralisib
541:NCT04191499
471:CITADEL-310
462:CITADEL-302
448:Parsaclisib
383:PROTECTOR 2
375:PROTECTOR 1
246:NCT02859727
242:NCT02435173
200:fulvestrant
5233:Categories
5167:Verdinexor
5162:Venetoclax
5065:Oblimersen
5060:Navitoclax
5035:Lucanthone
5030:Lonidamine
5020:Lifileucel
5015:Ivosidenib
5010:Imetelstat
4980:Enasidenib
4970:Elesclomol
4935:Bexarotene
4930:Belzutifan
4865:Bexarotene
4853:Atrasentan
4828:Umbralisib
4823:Idelalisib
4813:Copanlisib
4795:Vorinostat
4790:Romidepsin
4780:Entinostat
4775:Belinostat
4733:Masoprocol
4721:Tiazofurin
4709:Anagrelide
4681:Bortezomib
4668:Seliciclib
4663:Ribociclib
4643:inhibitors
4633:Tipifarnib
4596:Temoporfin
4591:Talaporfin
4529:Plicamycin
4524:Mitomycins
4470:Pipobroman
4449:Hydrazines
4415:Nedaplatin
4367:Carboquone
4362:Aziridines
4353:Treosulfan
4301:Carmustine
4288:Uramustine
4257:Ifosfamide
4229:Alkylating
4190:Bisantrene
4179:Pixantrone
4152:Valrubicin
4142:Idarubicin
4137:Epirubicin
4083:Teniposide
4038:Lurtotecan
4033:Irinotecan
3934:Decitabine
3898:Cytarabine
3841:Pyrimidine
3830:Tioguanine
3820:Thiopurine
3809:Nelarabine
3793:Cladribine
3745:Pemetrexed
3728:Pemetrexed
3704:Folic acid
3644:Paclitaxel
3596:Vinflunine
3278:2022-03-09
3258:2022-03-09
3238:2022-03-09
3146:2022-03-17
3063:2022-03-17
2935:2022-03-04
2820:2022-03-17
2800:2022-03-09
2780:2022-03-07
2711:2022-03-17
2691:2022-03-18
2671:2022-03-17
2651:2022-03-04
2613:2022-03-07
2593:2022-03-17
2573:2022-03-17
2283:2022-03-21
2190:2022-03-04
1659:2022-10-06
1624:5 February
1518:Oncotarget
1392:(1): 1–8.
1051:(1): 201.
881:References
851:Wortmannin
847:inhibitor)
835:reversible
795:inhibitor)
752:GSK1059615
734:Omipalisib
698:GSK2636771
676:Voxtalisib
664:wortmannin
614:Pictilisib
572:Eganelisib
556:Apitolisib
537:Inavolisib
527:Zandelisib
484:LIMBER-313
480:LIMBER-304
434:Idelalisib
426:DYNAMO + R
400:ofatumumab
367:Dactolisib
333:The trial
324:Copanlisib
286:paclitaxel
275:Buparlisib
262:Late stage
224:Leniolisib
206:Umbralisib
164:Copanlisib
143:trade name
139:Idelalisib
112:p110 delta
108:p110 gamma
106:(PIK3CB),
102:(PIK3CA),
100:p110 alpha
81:idelalisib
46:rigosertib
38:dactolisib
30:idelalisib
26:copanlisib
5212:Phase III
5200:Withdrawn
5177:Vosaroxin
5157:Veliparib
5112:Sotorasib
5102:Selinexor
5096:Tretinoin
5086:Retinoids
5000:Glasdegib
4945:Celecoxib
4894:Adagrasib
4818:Duvelisib
4808:Alpelisib
4763:Rucaparib
4750:Niraparib
4691:Oprozomib
4653:Alvocidib
4519:Bleomycin
4476:Triazenes
4460:Etoglucid
4405:Cisplatin
4321:Nimustine
4315:Semustine
4311:Lomustine
4273:Melphalan
4200:Menogaril
4195:Crisnatol
4185:Amsacrine
4157:Zorubicin
4117:Amrubicin
4078:Etoposide
4053:Topotecan
4048:Silatecan
4043:Rubitecan
4028:Gimatecan
4013:Cositecan
4003:Belotecan
3679:inhibitor
3649:Tesetaxel
3639:Ortataxel
3634:Larotaxel
3629:Docetaxel
3591:Vindesine
2153:213379077
2137:: 32–34.
2027:233234876
1368:235437841
1026:234360275
770:TG100-115
670:Tenalisib
660:Sonolisib
521:SANDPIPER
517:Taselisib
508:GBM AGILE
500:Paxalisib
456:(FL) and
411:rituximab
389:Duvelisib
355:CHRONOS-4
347:rituximab
343:CHRONOS-3
335:CHRONOS-2
236:(APDS) /
188:Alpelisib
178:Duvelisib
154:rituximab
104:p110 beta
5050:Mitotane
4990:Eribulin
4758:Olaparib
4696:Ixazomib
4372:Thiotepa
4344:Busulfan
4023:Exatecan
3860:Carmofur
3568:assembly
3531: /
3478:19614567
3440:19584227
3391:20346656
3356:30635656
3326:Oncogene
2916:17766839
2761:25370471
2094:19671762
2019:33848462
1929:27803006
1870:29223745
1815:28576675
1730:28972011
1533:34504654
1504:17371252
1464:20103642
1406:17021257
1360:34127844
1294:24055012
1259:19143644
1221:19275602
1167:33275709
1118:58657824
1110:30649751
1075:34054126
1018:33970742
980:31686003
931:33801659
862:See also
831:LY294002
789:AEZS-136
764:PWT33597
728:Acalisib
712:LY294002
602:lymphoma
350:effects.
330:(iNHL):
316:Novartis
250:approved
182:Copiktra
88:isoforms
3979:S phase
3880:Tegafur
3694:S phase
3619:Taxanes
3555:M phase
3431:2718129
3347:6756013
2752:4287394
2085:2752877
1806:5549667
1721:5701526
1414:1906947
1351:9297732
1158:7727518
1066:8165101
971:7314312
922:8037248
825:IC87114
805:GNE-477
776:ZSTK474
758:MEN1611
740:AZD8835
692:AZD8186
686:AMG 319
531:COASTAL
493:PATHWAY
407:BRAVURA
308:BELLE-4
304:BELLE-3
300:BELLE-2
196:Pivikto
168:Aliqopa
146:Zydelig
67:. This
5195:WHO-EM
4804:(Pi3K)
3761:Purine
3564:Block
3476:
3438:
3428:
3389:
3354:
3344:
2914:
2759:
2749:
2151:
2092:
2082:
2025:
2017:
1927:
1868:
1813:
1803:
1728:
1718:
1531:
1502:
1462:
1412:
1404:
1366:
1358:
1348:
1292:
1257:
1219:
1165:
1155:
1116:
1108:
1073:
1063:
1024:
1016:
978:
968:
929:
919:
845:DNA-PK
841:PI-103
746:CAL263
704:SF1126
630:DNA-PK
359:R-CHOP
229:Joenja
214:CSNK1E
210:Ukoniq
192:Piqray
4716:IMPDI
4611:Other
3295:Blood
3079:Blood
2301:(PDF)
2149:S2CID
2023:S2CID
1700:Blood
1618:(FDA)
1614:U.S.
1596:(PDF)
1410:S2CID
1364:S2CID
1114:S2CID
1022:S2CID
338:2022.
282:BURAN
127:aging
92:PI3Ks
72:of a
4802:PIKI
4770:HDAC
4219:CCNS
3474:PMID
3436:PMID
3387:PMID
3352:PMID
2912:PMID
2757:PMID
2322:help
2090:PMID
2015:PMID
1925:PMID
1866:PMID
1811:PMID
1726:PMID
1626:2021
1529:PMID
1500:PMID
1460:PMID
1402:PMID
1356:PMID
1290:PMID
1255:PMID
1217:PMID
1163:PMID
1141:2020
1106:PMID
1071:PMID
1014:PMID
976:PMID
927:PMID
799:B591
652:and
482:and
302:and
194:and
116:PTEN
44:and
34:mTOR
4848:ERA
4704:PhI
4675:PrI
4640:CDK
4552:PDT
3550:MIs
3546:SPs
3537:L01
3466:doi
3426:PMC
3418:doi
3379:doi
3342:PMC
3334:doi
3303:doi
3299:122
3087:doi
3083:116
2902:doi
2747:PMC
2739:doi
2139:doi
2080:PMC
2072:doi
2007:doi
1915:doi
1858:doi
1801:PMC
1793:doi
1716:PMC
1708:doi
1704:130
1522:doi
1492:doi
1452:doi
1394:doi
1390:321
1346:PMC
1338:doi
1282:doi
1247:doi
1209:doi
1153:PMC
1145:doi
1098:doi
1061:PMC
1053:doi
1006:doi
966:PMC
958:doi
917:PMC
907:doi
793:ERK
547:In
396:DUO
266:In
150:FDA
90:of
5235::
5208::
4728:LI
4628:FI
4094:II
4064:II
3886:))
3472:.
3462:37
3460:.
3434:.
3424:.
3412:.
3408:.
3385:.
3375:20
3373:.
3350:.
3340:.
3330:38
3328:.
3324:.
3297:.
3081:.
2988:.
2910:.
2896:.
2892:.
2755:.
2745:.
2735:21
2733:.
2729:.
2313::
2311:}}
2307:{{
2147:.
2133:.
2129:.
2088:.
2078:.
2066:.
2062:.
2021:.
2013:.
2003:22
2001:.
1923:.
1911:28
1909:.
1905:.
1864:.
1854:19
1852:.
1809:.
1799:.
1789:18
1787:.
1783:.
1724:.
1714:.
1702:.
1698:.
1668:^
1652:.
1612:.
1575:.
1498:.
1488:35
1486:.
1472:^
1458:.
1448:70
1446:.
1434:^
1408:.
1400:.
1388:.
1376:^
1362:.
1354:.
1344:.
1334:20
1332:.
1328:.
1302:^
1288:.
1278:40
1276:.
1253:.
1243:37
1241:.
1229:^
1215:.
1205:16
1203:.
1161:.
1151:.
1139:.
1135:.
1112:.
1104:.
1094:42
1092:.
1069:.
1059:.
1047:.
1043:.
1020:.
1012:.
1002:31
1000:.
988:^
974:.
964:.
954:20
952:.
948:.
925:.
915:.
903:22
901:.
897:.
809:50
551::
413:+
270::
129:.
94:.
5098:)
5089:(
4921:)
4917:/
4913:(
4879:)
4875:(
4867:)
4863:(
4855:)
4851:(
4830:)
4806:(
4797:)
4773:(
4765:)
4743:(
4735:)
4731:(
4723:)
4719:(
4711:)
4707:(
4670:)
4646:(
4635:)
4631:(
4603:)
4584:(
4550:/
4531:)
4512:(
4493:)
4479:(
4456:)
4452:(
4364::
4355:)
4346:(
4341::
4317:)
4313:(
4298::
4279:)
4275:(
4264:)
4255:(
4240::
4221:)
4217:(
4181:)
4167:(
4159:)
4128:)
4124:(
4110:(
4096:+
4085:)
4076:(
4055:)
4001:(
3989:I
3981:)
3977:(
3961:)
3957:(
3936:)
3927:(
3917:)
3913:(
3903:)
3896:(
3882:(
3853:(
3832:)
3823:(
3805:)
3791:(
3786:/
3777:)
3773:(
3752:)
3743:(
3735:)
3716:(
3696:)
3692:(
3663:)
3659:(
3651:)
3622:(
3603:)
3579:(
3557:)
3553:(
3548:/
3539:)
3535:(
3520:e
3513:t
3506:v
3480:.
3468::
3442:.
3420::
3414:8
3393:.
3381::
3358:.
3336::
3309:.
3305::
3281:.
3261:.
3241:.
3149:.
3093:.
3089::
3066:.
2938:.
2918:.
2904::
2898:6
2823:.
2803:.
2783:.
2763:.
2741::
2714:.
2694:.
2674:.
2654:.
2616:.
2596:.
2576:.
2500:.
2324:)
2320:(
2286:.
2193:.
2155:.
2141::
2135:4
2096:.
2074::
2068:8
2029:.
2009::
1931:.
1917::
1872:.
1860::
1817:.
1795::
1732:.
1710::
1662:.
1639:.
1628:.
1524::
1506:.
1494::
1466:.
1454::
1416:.
1396::
1370:.
1340::
1296:.
1284::
1261:.
1249::
1223:.
1211::
1169:.
1147::
1120:.
1100::
1077:.
1055::
1049:6
1028:.
1008::
982:.
960::
933:.
909::
853:(
833:(
817:(
682:.
656:.
202:.
141:(
55:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
